Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06636123 · ClinicalTrials.gov registry record · Phase 1
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
A Phase 1 study of Castration-resistant Prostate Cancer, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06636123: Recruiting Phase 1 study of Castration-resistant Prostate Cancer, sponsored by Virginia Commonwealth University.
NCT06636123 is a Phase 1 study of Castration-resistant Prostate Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 30 participants, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06636123, a Phase 1 study of Castration-resistant Prostate Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
Primary Outcome
Number of participants with rPFS for 6 months or longer
Conditions Studied
Interventions
- DRUG Investigational Agent Administration
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 1 |
What NCT06636123 shows while recruiting
NCT06636123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 215-participant average among 15 other Castration-resistant Prostate Cancer trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Castration-resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Investigational Agent Administration is the first listed.
NCT06636123 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06636123 about?
NCT06636123 is a clinical study titled "GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy". The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
What is the current status of trial NCT06636123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-18. Estimated completion is 2031-10-31.
What conditions does trial NCT06636123 study?
This clinical trial studies the following conditions: Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT06636123?
The interventions under investigation include: Investigational Agent Administration (DRUG).
Who is sponsoring clinical trial NCT06636123?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06636123 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06636123's enrollment target sits among peer trials
30 13th of 15 higher than 2 of 15 other Castration-resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Castration-resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RECRUITING · Phase 1
-
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
COMPLETED · Phase 1
-
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI